{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:08:59Z","timestamp":1791493739847,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12094-020-02467-8","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T13:39:54Z","timestamp":1597412394000},"page":"764-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct00261703","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"R.","family":"Hitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez-Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berrocal-Jaime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garc\u00eda-Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mart\u00ednez-Trufero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lambea-Sorrosal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"del Barco-Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Le\u00f3n-Vintr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Cunquero-Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Baste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1980-2751","authenticated-orcid":false,"given":"J. J.","family":"Cruz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Spanish Head and Neck Cancer Cooperative Group (TTCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"2467_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17346 patients. Radiother Oncol. 2009;92:4\u201314.","journal-title":"Radiother Oncol"},{"key":"2467_CR2","volume-title":"WHO Classification of head and neck tumours. WHO classification of head and neck tumours","author":"AK El-Naggar","year":"2017","unstructured":"El-Naggar AK, Chan JKC, Takata T, Slootweg PJ. WHO Classification of head and neck tumours. WHO classification of head and neck tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2017.","edition":"4"},{"key":"2467_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11864-019-0599-4","volume":"20","author":"MG Ghi","year":"2019","unstructured":"Ghi MG, Paccagnella A. Therapeutic intensification and induction chemotherapy for high-risk locally advanced squamous cell carcinoma. Curr Treat Options Oncol. 2019;20:2.","journal-title":"Curr Treat Options Oncol"},{"key":"2467_CR4","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","volume":"33","author":"ML Gillison","year":"2015","unstructured":"Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235\u201342.","journal-title":"J Clin Oncol"},{"key":"2467_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/annonc\/mdt461","volume":"25","author":"R Hitt","year":"2014","unstructured":"Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216\u201325.","journal-title":"Ann Oncol"},{"key":"2467_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"AA Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091\u20138.","journal-title":"N Engl J Med"},{"key":"2467_CR7","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705\u201315.","journal-title":"N Engl J Med"},{"key":"2467_CR8","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695\u2013704.","journal-title":"N Engl J Med"},{"key":"2467_CR9","first-page":"2206","volume":"28","author":"MG Ghi","year":"2017","unstructured":"Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codeca C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial Ann Oncol. 2017;28:2206\u201312.","journal-title":"A phase II-III trial Ann Oncol"},{"key":"2467_CR10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EE Cohen","year":"2014","unstructured":"Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735\u201343.","journal-title":"J Clin Oncol"},{"key":"2467_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257\u201364.","journal-title":"Lancet Oncol"},{"issue":"15","key":"2467_CR12","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1200\/JCO.2016.34.15_suppl.6001","volume":"34","author":"R Hitt","year":"2016","unstructured":"Hitt R, Mesia R, Grau JJ, Iglesias L, Del Barco E, Lozano A, et al. Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC). J Clin Oncol. 2016;34(15):6001.","journal-title":"J Clin Oncol"},{"key":"2467_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02467-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:06:05Z","timestamp":1628895965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2467"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02467-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"R. Hitt has received honoraria for advisory role from Merck. L. Iglesias has received honoraria for advisory role from Merck, Serono, MSD, BMS, Bayer, Sanofi, AstraZeneca, Novartis and Kura Oncology. A. Berrocal-Jaime has received honoraria for advisory role from BMS, MSD, Roche, Novartis, Pierre Fabre, Merck, Pfizer, Sanofi and Incyte. J. Mart\u00ednez-Trufero has received honoraria for advisory role from Pharmamar, Merck, Lilly, Eisai, BMS and Bayer. J. Lambrea-Sorrosal has received honoraria for advisory role from Merck, Sanofi, MSD and BMS. E. del Barco-Morillo has received honoraria for advisory role from Roche and AstraZeneca. A. J. Cunquero-Tomas has received honoraria for advisory role from Novartis, Roche, Merck, BMS and Pierre-Fabr\u00e9. N. Baste has received honoraria for advisory role from Merck, Nanobiotics, AstraZeneca, MSD and BMS. J. J. Cruz has received honoraria for advisory role from Merck, BMS, MSD, Roche, Astra Zeneca and Novartis. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted following the local and national regulations (Spanish agency: Agencia Nacional del Medicamento), including the ethical approval of the ethics committee in each hospital and in compliance with the Helsinki declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients received and signed an informed consent following the local and national regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}